Mechanism of Action of Megestrol Acetate in Endometriosis
Megestrol acetate works in endometriosis by directly suppressing endometrial tissue proliferation through progesterone receptor activation, while simultaneously inhibiting pituitary gonadotropin production to reduce estrogen secretion, creating an unfavorable hormonal environment for endometriotic lesions. 1
Primary Mechanisms
Direct Tissue Effects
- Megestrol acetate induces pseudodecidualization and atrophic changes in both eutopic endometrium and ectopic endometriotic implants, causing the tissue to become inactive and regress 2
- The drug exerts a direct cytotoxic effect on endometrial cells, modifying cellular function through progesterone receptor-mediated pathways 1
- It interferes with estrogen receptor stability and availability, preventing estrogen from stimulating endometriotic tissue growth 1
Hormonal Suppression
- Megestrol acetate inhibits pituitary gonadotropin (LH and FSH) production, which subsequently decreases ovarian estrogen secretion 1
- This creates a hypoestrogenic environment that starves endometriotic lesions of the estrogen they require for proliferation 2
- Ovulation is suppressed in all patients, eliminating cyclic hormonal fluctuations that can exacerbate endometriosis 2
Molecular Mechanisms
Receptor-Level Actions
- The drug modifies progesterone receptor expression (PR-A and PR-B ratio), maintaining tissue quiescence 3
- It interacts directly with the genome to turn off specific estrogen-responsive genes, preventing estrogen-mediated tissue proliferation 1
- Megestrol acetate can work through both genomic and non-genomic pathways, providing multiple points of therapeutic intervention 3
Anti-Inflammatory Effects
- Progestins like megestrol acetate decrease prostaglandin synthesis and infection-mediated cytokine production in endometrial tissues 3
- This anti-inflammatory action counteracts the inflammatory cascade that contributes to endometriosis-related pain 3
Clinical Implications for Reproductive-Age Women
Important Considerations
- Megestrol acetate does NOT improve future fertility outcomes and should not be used in women actively seeking pregnancy 4
- The mechanism requires continuous suppression of the hypothalamic-pituitary-ovarian axis, making conception impossible during treatment 2
- 86% of patients experience relief of disease-related symptoms (dysmenorrhea, pelvic pain, dyspareunia) through these combined mechanisms 5
Practical Effects
- Amenorrhea occurs in approximately 75% of patients due to endometrial suppression, though breakthrough bleeding can occur in 20% 2
- The drug's effects are reversible upon discontinuation, with ovarian function typically returning 2
- Serum LH decreases from 9.5 to 5.2 IU/L and estradiol from 80 to 46 pg/mL during treatment, demonstrating measurable hormonal suppression 2
Comparison to Other Progestins
- Megestrol acetate may be particularly effective in patients who have failed other hormonal therapies, as demonstrated in studies where 86% of previously treatment-resistant patients responded 5
- Unlike GnRH agonists, megestrol acetate does not cause severe hypoestrogenic symptoms or significant bone mineral density loss 6
- The mechanism is similar to other progestins (medroxyprogesterone acetate, norethisterone) but may have different potency and side effect profiles 7, 8